O
Opna Bio
Develops drugs targeting the Hallmarks of Cancer
About Opna Bio
Opna Bio is a clinical-stage biopharmaceutical startup that focuses on the discovery and development of novel oncology therapeutics. The company was recently launched with a $38 million Series A financing round. The funds will be used to advance its oncology discovery program and a diversified pipeline of clinical and preclinical programs.
Read full description
The company's primary focus is on developing drugs that disrupt the actions of a new cancer target known as fragile X mental retardation protein (FMRP). This protein is often overexpressed in tumors and helps them evade the immune system. By targeting this protein, Opna Bio aims to improve the body's ability to fight cancer.
Opna Bio's pipeline includes OPN 6602, a leading EP300 CBP inhibitor, which is currently in preclinical development and expected to enter the clinic in 2024. EP300 CBP inhibitors are a type of drug that can block certain proteins in cancer cells, potentially slowing their growth.
The company operates in the biopharmaceutical market, serving clients such as hospitals and clinics that treat cancer patients. Its business model revolves around the research, development, and eventual sale of its oncology drugs. The company generates revenue through the sale of these drugs once they have been approved by regulatory bodies like the FDA.
The company is led by CEO and Board Director, Gideon Bollag, PhD. Dr. Bollag has a strong track record in the biopharmaceutical industry, having developed two FDA approved drugs and overseen the discovery of several others.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Epalinges, Switzerland
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 44.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, proteomics, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Opna Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2022 | $38M | $152M | Menlo Ventures · Longitude Capital · Northpond Ventures | ↗ |
| SPINOUT✓Other financing | Sep 2020 | $0 | — | EPFL Swiss Federal Polytechnic School of Lausanne | — |
Growth signals
Latest recorded traffic for Opna Bio is 2.6K monthly website visits, up 136.4% over the last three months. Opna Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Menlo Ventures
Longitude Capital
Northpond Ventures
Other known investors2 additional known investors
EPFL Swiss Federal Polytechnic School of Lausanne
Myeloma Investment Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Opna Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Opna Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.